Semaglutide injection is a GLP-1 receptor agonist used for the management of type 2 diabetes and, in certain formulations, for chronic weight management. It helps lower blood sugar by stimulating insulin release when glucose levels are high, reducing glucagon secretion, and slowing gastric emptying, which also helps control appetite. In addition to improving glycemic control, semaglutide has been shown to support significant weight reduction and may reduce the risk of major cardiovascular events in patients with type 2 diabetes and established heart disease. It is usually administered once weekly under medical supervision. Common side effects include nausea, vomiting, diarrhea, and abdominal discomfort, and it should be used cautiously in patients with a history of pancreatitis or certain thyroid conditions.